Comparison of recombinant and native pertactin of Bordetella pertussis

Vaccine

Volumn 29, Issue 10, 2011, Pages 1974-1980

  Xu, Yinghua ^a   Zhang, Shumin ^a   Bolgiano, Barbara ^b   Tan, Yajun ^a   Asokanathan, Cathy ^b   Zhang, Huajie ^a   Xing, Dorothy ^b   Wang, Junzhi ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Bordetella pertussis; Immunogenicity; Native; Pertactin; Protection; Recombinant; Structural; Vaccine

Indexed keywords

NATIVE PERTACTIN; PERTACTIN; PERTUSSIS VACCINE; RECOMBINANT PERTACTIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BORDETELLA PERTUSSIS; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLUORESCENCE SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BACTERIAL OUTER MEMBRANE PROTEINS; BLOTTING, WESTERN; BORDETELLA PERTUSSIS; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; LUNG; MICE; PERTUSSIS VACCINE; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 79951726657     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.110     Document Type: Article

References (43)

1. Bass J.W., Wittler R.R. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994, 13:343-345.
2. Takum T., Gara D., Tagyung H., Murhekar M.V. An outbreak of pertussis in Sarli Circle of Kurung-kumey district, Arunachal Pradesh, India. Indian Pediatr 2009, 46(11):1017-1020.
3. Sin M.A., Zenke R., Rönckendorf R., Littmann M., Jorgensen P., Hellenbrand W. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Pediatr Infect Dis J 2009, 28(3):242-244.
4. Berger F., Njamkepo E., Minaberry S., Mayet A., Haus-Cheymol R., Verret C., et al. Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy. Vaccine 2010, 28(32):5147-5152.
5. World Health Organization [Internet], Geneva: programmes and projects/immunization surveillance, assessment and monitoring/vaccine-preventable diseases/pertussis [updated 2010 March 26; cited 2010 November 23]. Available from: http://www.who.int/immunization_monitoring/diseases/pertussis/en/index.html.
6. Vermeer-deBondt P.E., Labadie J., Rümke H.C. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. Br Med J 1998, 316:902-903.
7. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996, 334:341-348.
8. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of two-component acellular vaccines, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
9. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16:1901-1906.
10. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposurwe to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
11. Leininger E., Roberts M., Kenimer F.G., Charles I.G., Fairweather N., Novotny P., et al. Pertactin, an Arg-Gly-Asp containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci USA 1991, 88:345-350.
12. Emsley P., Charles I.G., Fairweather N.F., Isaacs N.W. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature 1996, 381:90-92.
13. Shahin R.D., Brennan M.J., Li Z.M., Meade B.D., Manclark C.R. Characterization of the protective capacity and immunogenicity of the 69kD outer membrane protein of Bordetella pertussis. J Exp Med 1990, 171:63-73.
14. Loosmore S.M., Yacoob R.K., Zealey G.R., Jackson G.E., Yang Y.P., Chong P.S., et al. Hybrid genes over-express pertactin from Bordetella pertussis. Vaccine 1995, 13:571-580.
15. Hijnen M., van Gageldonk P.G., Berbers G.A., van Woerkom T., Mooi F.R. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif 2005, 41:106-112.
16. Romanos M.A., Clare J.J., Beesley K.M., Rayment F.B., Ballantine S.P., Makoff A.J., et al. Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties. Vaccine 1991, 9:901-906.
17. Xu Y., Wang Y., Tan Y., Zhang H., Wu L., Wang L., et al. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis. BMC Microbiol 2009, 9:274.
18. Charles I., Rodgers B., Musgrave S., Peakman T.C., Chubb A., Fairweather N., et al. Expression of P.69/pertactin from Bordetella pertussis in a baculovirus/insect cell expression system: protective properties of the recombinant protein. Res Microbiol 1993, 144:681-690.
19. Makoff A.J., Oxer M.D., Ballantine S.P., Fairweather N.F., Charles I.G. Protective surface antigen P69 of Bordetella pertussis: its characterization and very high expression levels in Escherichia coli. BioTechnology 1990, 8:1030-1033.
20. Roberts M., Tite J.P., Fairweather N.F., Dougan G., Charles I.G. Recombinant P.69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection. Vaccine 1992, 10:43-48.
21. He C.M. Purification and characterization of acellular pertussis vaccine in China. Prog Microbiol Immun 1989, 4:31-34.
22. Zhang H., Zhang S., Zhuang H., Lu F. Cytotoxicity of a novel fibroblast growth factor receptor targeted immunotoxin on human ovarian teraocarcinoma cell line. Cancer Biother Radiopharm 2006, 21:321-332.
23. Towbin H., Staehlin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
24. Bolgiano B., Crane D.T., Xing D., Williams L., Jones C., Corbel M.J. Physico-chemical analysis of Bordetella pertussis antigens. Biologicals 1999, 27:155-162.
25. Bolgiano B., Mawas F., Burkin K., Crane D.T., Saydam M., Rigsby P., et al. A retrospective study on the quality of Haemophilus influenza type b vaccines used in the UK between 1996 and 2004. Human Vaccines 2007, 3:176-182.
26. Xing D., Wirsing von König C.H., Newland P., Riffelmann M., Meade B.D., Corbel M., et al. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin Vaccine Immunol 2009, 16(3):303-311.
27. Das R.G., Xing D., Rigsby P., Newland P., Corbel M. International collaborative study: evaluation of proposed international reference reagent of pertussis antiserum (mouse) 97/642. Biologicals 2001, 29:137-148.
28. Xing D., Das R.G., Williams L., Canthaboo C., Tremmil J., Corbel M.J. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 1999, 17:565-576.
29. Hijnen M., Mooi F.R., van Gageldonk P.G., Hoogerhout P., King A.J., Berbers G.A. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun 2004, 72:3716-3723.
30. Raja S.M., Rawat S.S., Chattopadhyay A., Lala A.K. Localization and environment of tryptophans in soluble and membrane-bound states of a pore-forming toxin from Staphylococcus aureus. Biophys J 1999, 76:1469-1479.
31. Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 1999, 27:79-86.
32. Plotkin S.A., Cadoz M. Acelluar vaccine is efficacy trials. Pediatr Infect Dis J 1997, 16(9):913-914.
33. Raz R., Dagan R., Gallil A., Brill G., Kassis I., Koren R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 1996, 14(3):207-211.
34. Malkin E., Hu J., Li Z., Chen Z., Bi X., Reed Z., et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008, 26(52):6864-6873.
35. Ranke M.B. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars. Horm Res 2008, 69(1):22-28.
36. Kelly S.M., Price N.C. The application of circular dichroism to studies of protein folding and unfolding. Biochim Biophys Acta 1997, 1338:161-185.
37. Ferrer M.L., Duchowicz R., Carrasco B., Garcia de la Torre J., Acuna A.U. The conformation of serum albumin in solution: a combined phosphorescence depolarization-hydrodynamic modeling study. Biophys J 2001, 80:2422-2430.
38. Hijnen M., de Voer R., Mooi F.R., Schepp R., Moret E.E., van Gageldonk P., et al. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine 2007, 25:5902-5914.
39. King A.J., Berbers G., van Oirschot H.F., Hoogerhout P., Knipping K., Mooi F.R. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001, 147:2885-2895.
40. Kobisch M., Novotny P. Identification of a 68-kilodalton outer membrane protein as the major protective antigen of Bordetella bronchiseptica by using specific-pathogen-free piglets. Infect Immun 1990, 58:352-357.
41. Hellwig S.M., Rodriguez M.E., Berbers G.A., van de Winkel J.G., Mooi F.R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003, 188:738-742.
42. Robinson A., Ashworth L.A., Baskerville A., Irons L.I. Protection against intranasal infection of mice with Bordetella pertussis. Dev Biol Stand 1985, 61:165-172.
43. Guzman C.A., Walker M.J., Rohde M., Timmis K.N. Direct expression of Bordetella pertussis filamentous hemagglutinin in Escherichia coli and Salmonella typhimurium aroA. Infect Immun 1991, 59:3787-3795.